Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong, China.
Global Medical and Scientific Affairs, MSD Hong Kong, Hong Kong, China.
Hum Vaccin Immunother. 2023 Aug 1;19(2):2184605. doi: 10.1080/21645515.2023.2184605. Epub 2023 May 15.
Human papillomavirus (HPV) can cause several diseases, including cancers, in both sexes. In January 2020, the Hong Kong government launched a school-based vaccination program for girls 10-12 years of age with the 9-valent HPV (9vHPV) vaccine for the prevention of HPV-related diseases; however, boys were not included. The current study estimated the potential health and economic impact of a routine gender-neutral vaccination (GNV) approach compared with the current female-only vaccination (FOV) strategy. We used a dynamic transmission model, adapted to Hong Kong. The model estimates changes in HPV-related disease incidence and mortality, treatment costs (in 2019 Hong Kong dollars), quality-adjusted life years (QALY), and incremental cost-effectiveness ratios (ICERs) over a 100-year time horizon. The base case analysis compared FOV with the 9vHPV vaccine with routine GNV (coverage rate 70%) for the prevention of HPV-related diseases. Compared with a FOV approach, routine GNV with the 9vHPV vaccine is predicted to provide greater reductions in cumulative HPV-related disease incidence and mortality, as well as lower HPV-related treatment costs. In the base case analysis, the ICER was $248,354 per QALY for routine GNV. As compared with FOV, routine GNV fell below the cost-effectiveness ceiling of $382,046/year for Hong Kong. These results highlight the potential value of a routine GNV program with the 9vHPV vaccine among 12-year-olds in Hong Kong to reduce the public health and economic burden of HPV-related diseases.
人乳头瘤病毒（HPV）可导致两性的多种疾病，包括癌症。2020 年 1 月，香港政府启动了一项针对 10-12 岁女童的基于学校的疫苗接种计划，为女童接种 9 价 HPV（9vHPV）疫苗，以预防 HPV 相关疾病；然而，男孩未包括在内。本研究旨在评估常规性别中性疫苗接种（GNV）方法与当前女性专用疫苗接种（FOV）策略相比的潜在健康和经济影响。我们使用了适用于香港的动态传播模型。该模型估计 HPV 相关疾病发病率和死亡率、治疗成本（以 2019 年港元计）、质量调整生命年（QALY）和增量成本效益比（ICER）在 100 年时间内的变化。基础病例分析比较了 FOV 与 9vHPV 疫苗在预防 HPV 相关疾病方面的常规 GNV（覆盖率 70%）。与 FOV 方法相比，常规 GNV 联合 9vHPV 疫苗预计将减少 HPV 相关疾病的累积发病率和死亡率，并降低 HPV 相关治疗成本。在基础病例分析中，常规 GNV 的每 QALY 增量成本效益比为 248354 港元。与 FOV 相比，常规 GNV 低于香港 382046 港元/年的成本效益上限。这些结果突出了在香港为 12 岁儿童提供常规 GNV 联合 9vHPV 疫苗接种计划的潜在价值，以降低 HPV 相关疾病的公共卫生和经济负担。
